insights_auto
Why is DMN down 5.11%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€0.059
arrow_downward
-5.11%(-0.0032) 1D
Nov 20, 10:00:00 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
134.69M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
Open
€0.06
High
€0.06
Low
€0.06
Mkt. cap
134.69M
Avg. vol.
0.00
Volume
0.00
52-wk high
€1.80
52-wk low
€0.05
No. of employees
42
News stories
From web sources and news partners
Decatur Daily
·
26 minutes ago
S&P 500 sinks 3.7% and the Nasdaq composite goes negative for the year
Nacionale
·
2 hours ago
Will the S&P 500 end 2026 down for the year? It's about 65 points above zero with 27 trading days left
Honolulu Star-Advertiser
·
8 hours ago
Wall Street rout pushes S&P 500, Dow into correction
BigGo Finance
·
31 minutes ago
S&P 500 Falls for Seventh Straight Session, Enters Correction as AI Stock Rally Loses Steam
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB
CEOUlf Hannelius
Employees42
Founded1984
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitediamyd.com